DexCom (DXCM) ebitda was $1.1B in FY2025 (+37% YoY). The tables below show the complete quarterly and annual ebitda history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual EBITDA
Fiscal Year
EBITDA
YoY
2025
$1.1B
+37%
2024
$810M
+3%
2023
$790M
+40%
2022
$564M
+17%
2021
$481M
-1%
2020
$486M
+61%
2019
$302M
+646%
2018
-$55M
-169%
2017
$80M
+29%
2016
$62M
+70%
2015
$36M
-1%
2014
$37M
+1267%
2013
$3M
+109%
2012
-$31M
-12%
2011
-$28M
+18%
2010
-$34M
+5%
2009
-$35M
Recent Quarterly EBITDA
Quarter
EBITDA
Q1 2026
$310M
Q4 2025
$369M
Q3 2025
$297M
Q2 2025
$267M
Q1 2025
$177M
Q4 2024
$242M
Q3 2024
$205M
Q2 2024
$212M
Q1 2024
$152M
Q4 2023
$251M
Q3 2023
$246M
Q2 2023
$170M
Source: DXCM on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.